Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04YMH
|
||||
Former ID |
DAP000970
|
||||
Drug Name |
Lumiracoxib
|
||||
Synonyms |
Joicela; Prexige; Novartis brand of lumiracoxib; COX 189; COX189; COX-189; Lumiracoxib [USAN:INN]; Prexige (Novartis); Prexige (TN); Lumiracoxib (USAN/INN); 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid; 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antiinflammatory Agents
|
||||
Company |
Norvatis Phamaceuticals Corporation
|
||||
Structure |
Download2D MOL |
||||
Formula |
C15H13ClFNO2
|
||||
InChI |
InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
|
||||
InChIKey |
KHPKQFYUPIUARC-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 220991-20-8
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
6889610, 10251040, 12015303, 14898109, 17397805, 46227733, 46506378, 50069519, 50070561, 50071183, 50126342, 50146068, 57347306, 76715547, 81041141, 81145916, 92718829, 103562109, 104084914, 104430341, 121362203, 123043886, 125345177, 126628436, 126645712, 126669886, 128383506, 131305772, 134338241, 135106949, 136948146, 137001909, 139667196, 144162368, 144207115, 152034557, 160661707, 160661708, 160964604, 162009833, 162169214, 163108814, 164786748, 166237623, 170465597, 172659601, 175610946, 178100246, 179150172, 184545760
|
||||
SuperDrug ATC ID |
M01AH06
|
||||
SuperDrug CAS ID |
cas=220991208
|
||||
Target and Pathway | |||||
Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [537120] | |
KEGG Pathway | Arachidonic acid metabolism | ||||
Metabolic pathways | |||||
NF-kappa B signaling pathway | |||||
VEGF signaling pathway | |||||
TNF signaling pathway | |||||
Retrograde endocannabinoid signaling | |||||
Serotonergic synapse | |||||
Ovarian steroidogenesis | |||||
Oxytocin signaling pathway | |||||
Regulation of lipolysis in adipocytes | |||||
Leishmaniasis | |||||
Pathways in cancer | |||||
Chemical carcinogenesis | |||||
MicroRNAs in cancer | |||||
Small cell lung cancer | |||||
PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
References | |||||
Ref 536058 | Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. | ||||
Ref 539920 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2897). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.